Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2,...
October 24 2016 - 8:00AM
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon tetracycline chemistry, announced
today that it will host a conference call and live audio webcast on
Wednesday, November 2, 2016 at 8:30 AM ET to report third quarter
2016 financial results and provide an update on its clinical
development efforts for omadacycline for skin infections, community
acquired bacterial pneumonia, and urinary tract infections.
The audio webcast can be accessed under "Events and
Presentations" in the Investor Relations section of the Company's
website at www.paratekpharma.com.
Domestic investors wishing to participate in the call should
dial: 877-407-9039 and international investors should dial:
201-689-8470. The conference ID is 13648499. Investors can also
access the call at
http://public.viavid.com/index.php?id=121674.
Replays of the call will be available through November 16, 2016.
Domestic investors can access the replay by dialing 844-512-2921
and international investors can access the replay by dialing
412-317-6671. The PIN code to access the replay is
13648499.
About Paratek Pharmaceuticals, Inc.Paratek
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies based
upon its expertise in novel tetracycline chemistry. Paratek's lead
product candidate, omadacycline, is the first in a new class of
tetracyclines known as aminomethylcyclines, with broad-spectrum
activity against Gram-positive, Gram-negative and atypical
bacteria. In June 2016 Paratek announced positive efficacy data in
a Phase 3 registration study in ABSSSI demonstrating the efficacy
and safety of intravenous (IV) to oral omadacycline compared to
linezolid. A Phase 3 registration study for community acquired
bacterial pneumonia (CABP) comparing IV-to-oral omadacycline to
IV-to-oral moxifloxacin was initiated in November 2015.
Enrollment continues on track to report top line data as early as
the third quarter of 2017. A Phase 3 registration study in
ABSSSI comparing once-daily oral-only dosing of omadacycline to
twice-daily oral-only dosing of linezolid was initiated in August
2016. Top line data are expected as early as the second quarter of
2017. A Phase 1b study in uncomplicated urinary tract infections
(UTI) was initiated in May 2016. Top line data from this
study will be shared in November 2016. Omadacycline has
been granted Qualified Infectious Disease Product designation and
Fast Track status by the U.S. Food and Drug
Administration.
Omadacycline is a new once-daily oral and IV, well-tolerated
broad spectrum antibiotic being developed for use as empiric
monotherapy for patients suffering from serious community-acquired
bacterial infections, such as acute bacterial skin and skin
structure infections, community acquired bacterial pneumonia,
urinary tract infections and other community-acquired bacterial
infections, particularly when antibiotic resistance is of concern
to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a
well-tolerated, once-daily, oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory
properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the
development and commercialization of sarecycline. Paratek retains
all ex-U.S. rights. Allergan initiated two identical Phase 3
registration studies in December 2014 for sarecycline for the
treatment of moderate to severe acne vulgaris. Top line data are
expected in the first half of 2017.
For more information, visit www.paratekpharma.com.
CONTACTS:
Media Relations: |
|
Investor Relations: |
Michael Lampe |
|
Hans Vitzthum |
(484) 575-5040 |
|
LifeSci Advisors, LLC. |
michael@scientpr.com |
|
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Sep 2023 to Sep 2024